Cyclin E与晚期乳腺癌患者紫杉烷敏感性和预后的关系

Impact of Cyclin E on Sensitivity of Taxane-Containing Chemotherapy and Prognosis in the Patients with Advanced Breast Cancer

[目的]探讨Cyclin E表达与乳腺癌患者含紫杉烷化疗的敏感性和预后的关系。[方法]湖北省肿瘤医院2001～2004年晚期或复发转移的乳腺癌患者56例进行了含紫杉类药物的联合化疗,免疫组化检测Cyclin E表达水平。[结果]Cyclin E高表达率为34%(19/56),Cyclin E高表达与紫杉烷化疗有效率无明显联系(χ2=0.1,P=0.8)。然而,低表达Cyclin E的患者中位生存时间29.1个月(95%CI:25.7～32.7),明显长于高表达患者的23.4个月(95%CI:19.7～27.2)(Log-Rank=4.1,P=0.04)。[结论]在乳腺癌患者中,Cyclin E不能准确判断紫杉类药物的近期疗效,但Cyclin E高表达可能是提示长期预后差的生物标志之一。

[Purpose ] To investigate the impact of Cyclin E expression on sensitivity of taxane-eontaining chemotherapy in advanced breast cancer. [Methods] Fifty-six cases chemotherapy with advanced or recurrent breast cancer patients undergoing taxane-eontaining were enrolled from 2001 to 2004 in Hubei provincial cancer hospital. The expression of Cyclin E was detected by immunohistochemistry. [Results] High expression of Cyclin E was 34%（19/56）. There was no significant relationship between high expression of cyclin E and response rate （χ^2=0.1,P=0.8）. However, median overall survival time in patients with high cyclin E expression was 29.1 months（95%CI：25.7～32.7）, it was significantly longer than that in patient with low Cyclin E expression （23.4 months,95%CI：19.7～27.2）（Log Rank=4.1,P=0.04）. [Conclusion] Cycln E can not accurately predict short-term response with taxane, however it may be considered as a biomarker to indicate poor prognosis in long-term.